Xilio Therapeutics Adds Biotech Legal Veteran as CLO Amid Pipeline Push
Event summary
- Xilio Therapeutics appointed Ben Harshbarger as Chief Legal Officer on June 29, 2026.
- Harshbarger brings over 20 years of biopharmaceutical legal and executive experience.
- He previously served as CLO at Astria Therapeutics until its acquisition by BioCryst Pharmaceuticals.
- Xilio is advancing multiple masked immuno-oncology therapies, including XTX501.
The big picture
Xilio Therapeutics' appointment of Ben Harshbarger as CLO underscores its focus on strengthening legal and strategic leadership amid a critical phase of clinical development. The move comes as the company advances its pipeline of next-generation, multi-specific immuno-oncology therapies, leveraging its clinically-validated masking technology. This strategic hire suggests Xilio is positioning itself for potential future acquisitions or partnerships, similar to Harshbarger's past experiences at Astria Therapeutics and Novelion Therapeutics.
What we're watching
- Pipeline Execution
- Whether Xilio can advance its masked immuno-oncology therapies toward the clinic as planned, particularly XTX501.
- Strategic Leadership
- How Harshbarger's experience with biotech acquisitions and transitions will shape Xilio's operational strategy.
- Regulatory Dynamics
- The pace at which regulatory approvals may impact the timeline for Xilio's product candidates.
Related topics